Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Figitumumab (Primary) ; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Biomarker; Registrational; Therapeutic Use
- Acronyms ADVIGO
- Sponsors Pfizer
- 16 Apr 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 11 Mar 2010 Planned initiation date changed from 1 Apr 2010 to 1 Jul 2010 as reported by ClinicalTrials.gov.
- 11 Mar 2010 Planned end date changed from 1 Apr 2014 to 1 May 2014 as reported by ClinicalTrials.gov.